Portfolio Items

Clinical stage company developing a small molecule pan-ROCK inhibitor targeting pulmonary and fibrotic indications.

An immunotherapy company developing next-generation, transformative therapies for broad patient populations.

A clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer.

A next-generation RNA medicines company that is advancing a novel platform to enable precision targeting of RNA therapeutics for a

Engineering novel AAVs and developing the next generation of gene therapies.

A clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and

A clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction.